MNS (Synonyms: NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Name: MNS
Brand: MedChemExpress
SKU: HY-78263
Rating: 4.5 (1 reviews)

Cat. No.: HY-78263 Purity: 99.43%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells.

For research use only. We do not sell to patients.

MNS Chemical Structure

CAS No. : 1485-00-3

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Src Isoform Specific Products:

View All Isoforms

Lck Fyn Blk

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms

NLRP3 NLRP1 NOD1 NOD2

View All Integrin Isoform Specific Products:

View All Isoforms

αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

NLRP3 inflammasome

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	GI₅₀	1.7 μg/mL Compound: 4m	Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
DU-145	GI₅₀	1.8 μg/mL Compound: 4m	Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
HBL-100	IC₅₀	> 20 μM Compound: MNS	Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay	[PMID: 20850977]
HeLa	IC₅₀	3.9 μM Compound: 2	Inhibition of proteasomal turnover of p97-independent ODD-luciferase reporter substrate in human HeLa cells incubated for 120 mins by luciferase reporter gene assay Inhibition of proteasomal turnover of p97-independent ODD-luciferase reporter substrate in human HeLa cells incubated for 120 mins by luciferase reporter gene assay	[PMID: 33476933]
KM-20L2	GI₅₀	1.8 μg/mL Compound: 4m	Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
L02	IC₅₀	39.24 μM Compound: MNS	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35428012]
L02	IC₅₀	41.1 μM Compound: MNS	Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay	[PMID: 34506712]
MCF7	GI₅₀	0.58 μg/mL Compound: 4m	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
MDA-MB-231	IC₅₀	14 μM Compound: MNS	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 20850977]
NCI-H460	GI₅₀	2 μg/mL Compound: 4m	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
P388	ED₅₀	2 μg/mL Compound: 4m	Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
Platelet	IC₅₀	14 μM Compound: MNS	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins before thrombin challenge by turbidimetry analysis Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins before thrombin challenge by turbidimetry analysis	[PMID: 20850977]
Platelet	IC₅₀	7.2 μM Compound: MNS	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins before collagen challenge by turbidimetry analysis Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins before collagen challenge by turbidimetry analysis	[PMID: 20850977]
SF-268	GI₅₀	1.9 μg/mL Compound: 4m	Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]

In Vitro

MNS (48 h) shows cytotoxicity against human BxPC3, DU145, and KM20L2 cells, with GI₅₀ of 1.7 μg/mL, 1.8 μg/mL, 1.8 μg/mL, respectively^[3].
MNS (1-20 μM, 1-15 h) inhibits adhesion and migration of MDA-MB-231 cells by suppressing β1 integrin function and surface protein disulfide isomerase^[4].
MNS (1-10 μM, 15 min) inhibits NLRP3 inflammasome activation in LPS-primed BMDMs by blocking assembly of the inflammasome^[5].
MNS (2.5-10 μM, 4-24 h) decreases the motility and colony formation of osteosarcoma cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[4]

Cell Line:	MDA-MB-231
Concentration:	1, 2, 5, 10, 20 μM
Incubation Time:	15 h
Result:	Concentration-dependently prevented MDA-MB-231 cells from migrating. Failed to migrate into and close a wound at 10 and 20 μM. Abolished the migration at 5 μM.

In Vivo

MNS (20 mg/kg, i.p.) ameliorates experimental burn wound progression in Wistar rats by inhibiting the NLRP3 inflammasome activation^[7].
MNS (30 mg/kg, p.o., 5 days) alleviates DSS-induced mouse colitis by inhibiting the NLRP3 inflammasome^[8].
MNS (20 mg/kg, i.p., 30 min before reperfusion) significantly protects the kidneys from RIR injury in rats by reducing PANoptosis through specific inhibition of NLRP3^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

193.16

Formula

C₉H₇NO₄

CAS No.

1485-00-3

Appearance

Solid

Color

Light yellow to green yellow

SMILES

O=[N+]([O-])/C=C/C1=CC(OCO2)=C2C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (258.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.1771 mL	25.8853 mL	51.7706 mL
5 mM	1.0354 mL	5.1771 mL	10.3541 mL
10 mM	0.5177 mL	2.5885 mL	5.1771 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (12.94 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.55%

Select Batch:

Data Sheet (278 KB) SDS (420 KB)

COA (248 KB) HNMR (242 KB) LCMS (108 KB)

Handling Instructions (2659 KB)

References

[1]. Wang WY, et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007;74(4):601-611. [Content Brief]

[2]. Wang WY, et al. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006;70(4):1380-1389. [Content Brief]

[3]. Pettit RK, et al. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. Bioorg Med Chem. 2009 Sep 15;17(18):6606-12. [Content Brief]

[4]. Chen IH, et al. 3,4-Methylenedioxy-β-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing β1 integrin function and surface protein disulfide isomerase. Biochimie. 2015 Mar;110:81-92. [Content Brief]

[5]. He Y, et al. 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014 Jan 10;289(2):1142-50. [Content Brief]

[6]. Messerschmitt PJ, et al. Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene. Sarcoma. 2012;2012:479712. [Content Brief]

[7]. Xiao M, et al. 3,4-Methylenedioxy-β-Nitrostyrene Ameliorates Experimental Burn Wound Progression by Inhibiting the NLRP3 Inflammasome Activation. Plast Reconstr Surg. 2016 Mar;137(3):566e-575e. [Content Brief]

[8]. Zheng J, et al. 3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium-Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome. Front Pharmacol. 2022 Jun 15;13:866228. [Content Brief]

[9]. Uysal E, et al. Targeting the PANoptosome with 3,4-Methylenedioxy-β-Nitrostyrene, Reduces PANoptosis and Protects the Kidney against Renal İschemia-Reperfusion Injury. J Invest Surg. 2022 Nov-Dec;35(11-12):1824-1835. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.1771 mL	25.8853 mL	51.7706 mL	129.4264 mL
	5 mM	1.0354 mL	5.1771 mL	10.3541 mL	25.8853 mL
	10 mM	0.5177 mL	2.5885 mL	5.1771 mL	12.9426 mL
	15 mM	0.3451 mL	1.7257 mL	3.4514 mL	8.6284 mL
	20 mM	0.2589 mL	1.2943 mL	2.5885 mL	6.4713 mL
	25 mM	0.2071 mL	1.0354 mL	2.0708 mL	5.1771 mL
	30 mM	0.1726 mL	0.8628 mL	1.7257 mL	4.3142 mL
	40 mM	0.1294 mL	0.6471 mL	1.2943 mL	3.2357 mL
	50 mM	0.1035 mL	0.5177 mL	1.0354 mL	2.5885 mL
	60 mM	0.0863 mL	0.4314 mL	0.8628 mL	2.1571 mL
	80 mM	0.0647 mL	0.3236 mL	0.6471 mL	1.6178 mL
	100 mM	0.0518 mL	0.2589 mL	0.5177 mL	1.2943 mL

MNS Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

MNS (Synonyms: NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Customer Review

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Src Isoform Specific Products:

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Integrin Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MNS Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

MNS (Synonyms: NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Customer Review

MNS Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Src Isoform Specific Products:

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Integrin Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

MNS Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MNS Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report